Clinical trialNCT00532441TerminatedPhase 2Interventional

Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

SponsorGabi Chiorean, MDEnrollment25Hepatocellular Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

An unmet medical need exists for the successful therapy of patients with advanced hepatocellular and biliary tract malignances, with few and short lived disease responses to chemotherapy for both advanced stage hepatic and biliary carcinomas. Pre-clinical data shows cooperative antitumor activity between an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and taxanes. The efficacy of erlotinib in combination with docetaxel will be assessed in this trial.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Elena Gabriela Chiorean, M.D.
Hoosier Oncology Group, LLC
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Helen F. Graham Cancer Center
Newark, Delaware, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Rush-Presbyterian St. Luke'S Medical Center
Chicago, Illinois, United States
Cancer Care Center of Southern Indiana
Bloomington, Indiana, United States
Fort Wayne Oncology & Hematology, Inc
Fort Wayne, Indiana, United States
in Onc/hem Associates
Indianapolis, Indiana, United States
Indiana University Cancer Center
Indianapolis, Indiana, United States
Quality Cancer Center (mcgop)
Indianapolis, Indiana, United States
Medical Consultants, P.C.
Muncie, Indiana, United States
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States
Siteman Cancer Center
St Louis, Missouri, United States
Methodist Cancer Center
Omaha, Nebraska, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Docetaxel →Erlotinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2007
Primary completion: 31 Aug 2010
Completion: 31 Aug 2010
Last update posted: 12 Feb 2016
Registered enrollment: 25
Registry id: NCT00532441

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.